Multi‐Institutional Study of ALK‐Positive Large B‐Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies

Overview of attention for article published in American Journal of Hematology, September 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 14 X users

Readers on

mendeley: 6 Mendeley

So far, Altmetric has seen 16 X posts from 14 X users, with an upper bound of 13,710 followers.

RT @AjHematology: In the largest cohort of #ALK+ LBCL to date, poor outcomes persisted despite intensified frontline chemotherapy or frontl…

RT @AlbertYunes: Excited to share our multi-institutional study on ALK+ Large B-cell lymphoma in @AjHematology : Outcomes remain poor with…

RT @AjHematology: In the largest cohort of #ALK+ LBCL to date, poor outcomes persisted despite intensified frontline chemotherapy or frontl…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 12 additional X posts.